A Systematic Review of Clinically Significant Drug-Drug Interactions With Phenobarbital and Primidone - PubMed
4 hours ago
- #phenobarbital
- #drug interactions
- #CYP450
- Phenobarbital (PB) is used for seizure disorders and alcohol withdrawal syndrome.
- PB induces cytochrome-P 450 enzymes (CYP450), leading to drug-drug interactions (DDIs).
- A systematic review identified 50 studies on PB DDIs with anticoagulants, antimicrobials, and immunosuppressants.
- Onset of PB induction ranged from 6 hours to 30 days; offset ranged from 2 to 8 weeks.
- 86% of studies showed PB impacts outcomes, often related to therapeutic drug monitoring.
- PB causes clinically significant DDIs in multiple medication classes.
- Future research should focus on clinical outcomes and single high-dose PB effects.